COP27 takes place amid war in Ukraine and an energy crisis. In the third episode of our series covering the summit, we explore how energy-security concerns are affecting efforts to decarbonise.

Niklas Höhne of the NewClimate Institute says the energy crisis could deepen Europe’s dependence on fossil fuels. But Francesco La Camera, who leads the International Renewable Energy Agency, sees it as an opportunity to accelerate the green agenda. Plus, award-winning author Daniel Yergin explains the implications for Russia, and Jason Bordoff of Columbia University assesses the geopolitics of the transition to clean energy.

Alok Jha hosts with Catherine Brahic, The Economist’s environment editor, and Vijay Vaitheeswaran, our global energy and climate innovation editor.

Listen to our mini-series at economist.com/COP27pod and follow all of The Economist’s climate coverage at economist.com/climate-change.

For full access to The Economist’s print, digital and audio editions, subscribe at economist.com/podcastoffer and sign up for our weekly science newsletter at economist.com/simplyscience.

Hosted on Acast. See acast.com/privacy for more information.

COP27 has kicked off in Egypt, and adaptation is high on the agenda. In the second episode of our series covering the conference, we explore how to step up global efforts to adapt to a changing climate.

Edward McBride, The Economist’s briefings editor, travels to Iraq to investigate how a hotter world is affecting the way people live. Adeline Stuart-Watt, an adaptation policy fellow at the London School of Economics and Political Science, explains how to implement and finance climate-resilient projects.

Alok Jha hosts with Catherine Brahic, The Economist’s environment editor, and Vijay Vaitheeswaran, our global energy and climate innovation editor.

Listen to our mini-series at economist.com/COP27pod and follow all of The Economist’s climate coverage at economist.com/climate-change.

For full access to The Economist’s print, digital and audio editions, subscribe at economist.com/podcastoffer and sign up for our weekly science newsletter at economist.com/simplyscience.

Hosted on Acast. See acast.com/privacy for more information.

This week, the COP27 climate summit will begin in Egypt. In the first of four episodes, we consider the themes set to dominate the conference. After a year lacking in climate action, do lofty targets need a dose of realism? Plus, “loss and damage” financing is expected to be high on the agenda at the summit. We explore its patchy history, and explain why we think rich countries are unlikely to pay compensation to vulnerable ones for historic emissions.

Gavin Jackson, The Economist’s economics and finance correspondent, scrutinises debates on climate reparations. Fredi Otto, a climate scientist at Imperial College London, explains how carbon emissions can be attributed to climate disasters.

Alok Jha hosts with Catherine Brahic, The Economist’s environment editor, and Vijay Vaitheeswaran, our global energy and climate innovation editor.

Follow all of The Economist’s climate coverage at economist.com/climate-change.

For full access to The Economist’s print, digital and audio editions, subscribe at economist.com/podcastoffer and sign up for our weekly science newsletter at economist.com/simplyscience.

Hosted on Acast. See acast.com/privacy for more information.

The pandemic shattered global efforts to control tuberculosis, which was the most lethal infectious disease in the world until covid-19 took its crown. Now, with deaths rising, TB is set to reclaim that dubious honour. But the covid era also holds important lessons for the fight against TB. Can innovations such as genomic sequencing facilities and new vaccine technologies be applied to TB care, too?

Avantika Chilkoti, The Economist’s international correspondent, travels to Rio de Janeiro in Brazil to find out why TB is a disease of the poor. Mel Spigelman of the TB Alliance and Lucica Ditiu of the Stop TB Partnership say tackling the disease is a question of political will. Josefina Campos of ANLIS in Argentina explains how genomic sequencing helps monitor TB drug resistance. Author Vidya Krishnan talks about TB’s influence on art and culture. Plus, we examine why doctors are worried about the prospect of a new, highly contagious form of TB that doesn’t respond to existing drugs. Alok Jha hosts.

For full access to The Economist’s print, digital and audio editions subscribe at economist.com/podcastoffer and sign up for our weekly science newsletter at economist.com/simplyscience.

Hosted on Acast. See acast.com/privacy for more information.

The war in Ukraine has raised the nuclear threat to its highest level since the Cuban missile crisis. What types of nuclear weapons could be used in Ukraine, and how much damage could they do? 

Cheryl Rofer, a former nuclear scientist at America’s Los Alamos National Laboratory, describes the “tactical” nukes in Russia’s arsenal. Patricia Lewis, research director for international security at Chatham House, explains the destruction that would be wrought if the war turned nuclear. Plus, Shashank Joshi, The Economist’s defence editor, analyses whether Russia’s recent military setbacks increase the risk of nuclear conflict. Alok Jha hosts.

For full access to The Economist’s print, digital and audio editions subscribe at economist.com/podcastoffer and sign up for our weekly science newsletter at economist.com/simplyscience.

Hosted on Acast. See acast.com/privacy for more information.

Gene therapies border on the miraculous, transforming lives in a single shot. The treatments offer hope to millions around the world who live with genetic diseases, and could also help the fight against cancer and HIV. This year, four new gene therapies were approved—and there are thousands more clinical trials under way. But the path from miracles of science to miracles of medicine will not be easy. The Economist’s Natasha Loder explains the safety concerns and market challenges that must be overcome to make the genetic revolution possible. Alok Jha hosts.

For full access to The Economist’s print, digital and audio editions subscribe at economist.com/podcastoffer and sign up for our weekly science newsletter at economist.com/simplyscience.

Hosted on Acast. See acast.com/privacy for more information.

During the pandemic, wastewater monitoring became a valuable tool in spotting covid-19 infection waves and the arrival of new variants. But sewage surveillance can help track the spread of all kinds of diseases—and measure a population’s consumption of everything from vegetables to cocaine. The Economist’s Gilead Amit examines how spying on sewage could offer health agencies an unprecedented insight into the lives of local populations, and considers the privacy concerns that could arise. Plus, we speak to the founder of a company that monitors wastewater to track the opioid crisis in America. Alok Jha hosts.

For full access to The Economist’s print, digital and audio editions, subscribe at economist.com/podcastoffer and sign up for our weekly science newsletter at economist.com/simplyscience.

Hosted on Acast. See acast.com/privacy for more information.

Psychedelic drugs—such as LSD and psilocybin, the psychoactive compound found in magic mushrooms—may be coming to the medicine cabinet. Research into their use to treat mental-health conditions was long blocked by law and stigma. But in recent years, there has been a revival of interest in the drugs, which are now being trialled to treat conditions such as depression. The Economist’s Ainslie Johnstone visits one of Britain's most high-profile psilocybin research facilities, and investigates how the drug could help scientists better understand autism. And, as investors pile in, Natasha Loder, our health policy editor, separates the hope from the hype. Plus, we ask whether the drugs’ hallucinatory effects are necessary for their health benefits, and meet a researcher who hopes to develop psychedelics without the trip. Alok Jha hosts.

Listen to our other episodes on psychedelics in health care at economist.com/psychedelics-pod.

For full access to The Economist’s print, digital and audio editions subscribe at economist.com/podcastoffer and sign up for our weekly science newsletter at economist.com/simplyscience.

Hosted on Acast. See acast.com/privacy for more information.

During the pandemic, scientists gained greater prominence in the lives of ordinary people than ever before. And while covid-19 highlighted the importance of the field to humanity, it also raised questions about the role of scientists in modern life. Host Alok Jha talks to the astronomer and cosmologist Martin Rees, one of Britain’s top scientists and a former president of the Royal Society. His new book “If Science is to Save Us” argues that scientific knowledge can solve some of the world’s biggest problems, but it can also lead to great harm. He tells us about the three looming “mega-catastrophes” that worry him most, and how to encourage innovation in scientific research.

For full access to The Economist’s print, digital and audio editions subscribe at economist.com/podcastoffer and sign up for our weekly science newsletter at economist.com/simplyscience.

Hosted on Acast. See acast.com/privacy for more information.

A monumental shift is about to take place in the crypto world. One of the most important blockchain projects, Ethereum, is set to change the way it secures its network—from the energy-intensive “proof-of-work” system to the greener “proof-of-stake” method. Known as “the merge”, the switch could slash Ethereum’s energy consumption by over 99 percent. The Economist’s Stevie Hertz investigates why the “proof-of-work” system of mining currencies like bitcoin is so bad for the environment, and Alice Fulwood and Ludwig Siegele analyse how Ethereum’s merge will change the wider cryptoverse. Alok Jha hosts.

For full access to The Economist’s print, digital and audio editions subscribe at economist.com/podcastoffer and sign up for our weekly science newsletter at economist.com/simplyscience.

Hosted on Acast. See acast.com/privacy for more information.